[F:1][C:2]1[CH:7]=[CH:6][CH:5]=[C:4]([F:8])[C:3]=1[C:9]1[CH:10]=[C:11]2[C:15](=[CH:16][CH:17]=1)[NH:14][CH:13]=[C:12]2[C:18]1[CH:23]=[C:22]([O:24][CH3:25])[N:21]=[C:20]([N:26]2[CH2:31][CH2:30][CH:29]([NH:32]C(=O)OC(C)(C)C)[CH2:28][CH2:27]2)[N:19]=1.Cl>O1CCOCC1>[F:8][C:4]1[CH:5]=[CH:6][CH:7]=[C:2]([F:1])[C:3]=1[C:9]1[CH:10]=[C:11]2[C:15](=[CH:16][CH:17]=1)[NH:14][CH:13]=[C:12]2[C:18]1[CH:23]=[C:22]([O:24][CH3:25])[N:21]=[C:20]([N:26]2[CH2:31][CH2:30][CH:29]([NH2:32])[CH2:28][CH2:27]2)[N:19]=1To solution of tert-butyl (1-(4-(5-(2,6-difluorophenyl)-1H-indol-3-yl)-6-methoxypyrimidin-2-yl)piperidin-4-yl)carbamate (0.1 g, 0.187 mmol) in dioxane (2 mL) was added HCl in dioxane (2 mL) and the mixture was heated at 90° C. for overnight. The reaction was quenched with aq.NaHCO3 and extracted with EtOAc. The organic layer was dried (Na2SO4), filtered and concentrated. The residue was purified with basic alumina column chromatography. (eluting in 1% MeOH in CHCl3) to give 1-(4-(5-(2,6-difluorophenyl)-1H-indol-3-yl)-6-methoxypyrimidin-2-yl)piperidin-4-amine (20 mg, 25%). MS (ESI, pos. ion) m/z: 436.1 (M+1); 1H-NMR (DMSO-d6, 400 MHz): δ ppm 11.84 (brs, 1H), 8.58 (s, 1H), 8.29 (s, 1H), 7.56 (d, 1 H, J=8.4 Hz), 7.47-7.43 (m, 1H), 7.19-7.27 (m, 3H), 6.54 (s, 1H), 4.7 (d, J=12 Hz, 2H), 3.8 (s, 3H), 3.0 (t, J=12 Hz, 2H), 1.85-1.89 (m, 3H), 1.38-1.40 (m, 2H).
読み込み中…